SaferSkin™
- integrated skin sensitisation assessment

An estimated 15-20% of the general population suffers from allergic contact dermatitis, or skin sensitisation. In fact, skin sensitisation is considered the most prevalent form of immunotoxicity found in humans, responsible for over seven million outpatient visits annually.*

SaferSkin™ is an easy-to-use software application which helps you determine, with confidence, the skin sensitisation potency of a substance according to accepted OECD guidelines. Applying three different and well-accepted scientific approaches, SaferSkin™ assesses input data, assigns a sensitisation category and calculates the level of confidence in the prediction. In one step, SaferSkin™ can help you make the best decisions in line with regulatory guidelines and best industry practices. SaferSkin™ supports the principles of the 3Rs of animal testing (Reduction, Refinement, Replacement) for more humane research.

Openness and transparency is in our company’s DNA so the SaferSkin™ Basic version is free and available to the global community. SaferSkin™ Professional offers additional and more advanced features at an affordable rate. The Enterprise version offers you the opportunity to define features for SaferSkin™ that are customised to your specific needs.

SaferSkin™ is the first of a range of chemical safety applications we have in the pipeline.

Get in touch for a free trial, or visit https://saferworldbydesign.com/saferskin/

* Kimber I, Basketter DA, Gerberick GF, Dearman RJ (2002). "Allergic contact dermatitis". Int. Immunopharmacol. 2 (2–3): 201–11. doi:10.1016/S1567-5769(01)00173-4. PMID 11811925